The Centers for Disease Control and Prevention (CDC) recommends that people who are moderately to severely immunocompromised receive a booster mRNA COVID-19 vaccine (Pfizer or Moderna) at least 28 days after the completion of the initial vaccine.
This immunocompromised group includes patients who have:
- Active treatment for solid tumor and hematologic malignancies
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of CAR-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids (i.e., ≥20mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory.
People who need an additional dose and received either the Pfizer or Moderna vaccine series are recommended to receive a third dose of the same vaccine used. If you are unable to get the same vaccine type as the initial series, you may use the alternative (Moderna or Pfizer).
Find a Vaccine Location Near You
The mRNA COVID-19 primary and booster vaccines are available in local pharmacies, supermarkets, and other community resources. Find a COVID-19 vaccine near you at www.vaccines.gov.
Schedule Your Booster with TGMG
We also offer mRNA COVID-19 vaccines in our TGMG primary care clinics on certain days. Schedule your COVID-19 primary or booster vaccine through your MyChart account.
Important Info for Transplant Patients
Please contact your transplant coordinator for appropriateness of the COVID-19 vaccine if any of the following apply:
- If you received an organ transplant in the past 30 days
- Had a hospital admission in the past 30 days
- Have been exposed to COVID-19 within the past 48 hours
Important Info for Cancer Patients
Please contact your oncology team for appropriateness of the COVID-19 vaccine if any of the following apply:
- Acute leukemia patients in active treatment
- Lymphoma patients receiving anti-CD20 Monoclonal antibodies (rituximab, obinutuzumab, ofatumumab) as part of their treatment
The above group of patients may also benefit with an anti-COVID monoclonal antibodies if recent high risk exposure.
Not sure if you qualify?
Contact your doctor, specialist or transplant coordinator.
To receive a booster vaccine, patients must meet immunocompromoised eligibility as defined by the CDC.